SGLT2 inhibitors combined with finerenone reduce major adverse kidney events compared to SGLT2 inhibitor or finerenone monotherapy
Current assessment
Synthesis pending
Confidence
Not assessed
Supporting evidence (0)
Nothing recorded on this side
Contradicting evidence (0)
Nothing recorded on this side
Discussion (0)
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.